Dr. Scott M. Rocklage is the managing partner of Menlo Park, California bas 5AM Ventures. A very successful entrepreneur and experienced business executive, Dr. Rocklage spent more than 20 years working in leadership positions in the healthcare industry before joining the company in 2003. He also played a major role in getting Food and Drug Administration approval for three new drugs, Cubicin®, Teslascan® and Omniscan™. Dr. Rocklage has also worked to get six drug candidates entered into clinical trials.
Prior to working with 5AM Ventures, Dr. Scott Rocklage was Cubist Pharmaceuticals’ chairman and CEO. He was also CEO and president of Nycomed Salutar and served as Nycomed Interventional’s chairman, president and CEO. Dr. Scott Rocklage also worked in research and development with Salutar and Catalytica. In addition to his role with 5AM Ventures, Dr. Rocklage is currently Achaogen, Relypsa and Semprus’ board chairman and on the WaveRx, Pulmatrix and Variation board of directors and the Whitehead Institute board of associates. He has also been executive chairman of Miikana and Ilypsa.
As an undergraduate, Scott Rocklage attended the University of California, Berkeley where he earned a bachelor’s degree in Chemistry. He then went on to the Massachusetts Institute of Technology where he did a Ph.D. in Chemistry. While at MIT, Dr. Rocklage did research in 2005 Noble Prize winner Richard R. Schrock’s laboratory. Scott Rocklage has more than 30 U.S. patents where he is listed as either the inventor or co-inventor. A prolific writer, he has had his work appear in over 100 peer-reviewed publications.
5AM Ventures is venture capital firm that invests in early stage life science-based companies. From his office in Waltham, Massachusetts Dr. Rocklage studies new life science ideas and helps business-executives, physicians and scientists turn their ideas into medicines to treat pressing medical issues. He also works with the company’s portfolio management team.
One of the areas in which Dr. Rocklage is very interested in is biomedical developments. Those advances help to create unique medical techniques and technologies designed to target specific genotypes and mutations and discover new and better ways to treat cancer and save lives.
Connect with Dr. Scott Rocklage on LinkedIn for more information.